Utilizing EZH2 Inhibition to Improve Immune Therapies in Follicular Lymphoma

Wendy Béguelin, PhD,
Weill Cornell Medicine

Utilizing EZH2 Inhibition to Improve Immune Therapies in Follicular Lymphoma Technical abstract: Follicular lymphoma (FL) is an indolent disease, and the primary clinical goal in managing FL is to prolong survival while optimizing quality of life by minimizing...

Dual CD19-CAR-T approaches to counteract antigen escape and tumor microenvironment immune suppression in FL

Patricia Pérez-Galán, PhD,
Institut d’Investigacions Biomèdiques August Pi I Sunyer

Dual CD19-CAR-T approaches to counteract antigen escape and tumor microenvironment immune suppression in FL. Technical abstract: CAR-T cell therapy resistance may appear linked to antigen loss and/or an immunosuppressive tumor microenvironment (TME). We hypothesized...

Engaging the inhibitory BTLA Receptor for the Treatment of Follicular Lymphoma

Hans-Guido Wendel, MD, PhD
Memorial Sloan Kettering Cancer Center

Engaging the inhibitory BTLA Receptor for the Treatment of Follicular Lymphoma Technical abstract: CAR T cell therapies have proven extremely powerful against B cell malignancies. However, there is no specialized CAR T to eliminate FL. We discovered that the...

Research in focus: Bi-specific antibodies approval.

Research in focus: Bi-specific antibodies approval. By Dr. Zoe Drymoussi Over the last few years, a promising new class of treatments for advanced-stage FL has been in development, with mosunetuzumab being the first in this class to be approved in Europe (by the EMA;...

FLF are attending the ASH 2022 Annual Meeting

FLF are attending the ASH 2022 Annual Meeting We are delighted that some of the team are able to attend the 64th ASH Annual Meeting and Exposition, in New Orleans Louisiana, USA from the 10th to the 13th December 2022.The FLF team will be attending sessions, building...